# Diagnoplex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/diagnoplex

- Industry: Biotechnology
- Headquarters: Switzerland
- Website: www.diagnoplex.com
- Total disclosed funding: $8.5M
- Latest round: Series A (Dec 10, 2008)
- Investors on record: 3

## About

Diagnoplex is a domain name sales and leasing company, providing comprehensive services for individuals and businesses to secure their online presence efficiently.Diagnoplex operates in the domain name industry, offering sales and leasing options for online identities. The company was acquired by Novigenix SA in February 2015. Diagnoplex is headquartered in Switzerland. The funding round led by Debiopharm Group raised CHF 1.300 mn, which is the total amount raised by the company through various investments.Diagnoplex.com specializes in the sale and lease of domain names, offering a streamlined platform for individuals and businesses seeking to establish their online presence. The core product offerings include the option to purchase domains outright for CHF 3,995 or to engage in a Lease to Own program at a monthly rate of CHF 192. These services cater to a diverse clientele, including entrepreneurs, small business owners, and large corporations looking to secure a distinctive online identity. The company emphasizes user-friendly transactions, providing features such as secure payments and free transaction support, ensuring that customers can easily navigate the process of acquiring domain names. Diagnoplex.com serves clients primarily in the United States but is open to international customers, providing local currency options at checkout to facilitate global transactions.Revenue generation for Diagnoplex.com is structured primarily through direct-to-consumer sales and leasing agreements. Customers have the option to purchase domain names outright or enter a Lease to Own arrangement, allowing for flexible payment solutions tailored to their financial needs. The pricing strategy includes a one-time purchase fee of CHF 3,995 for full ownership or a monthly payment plan of CHF 192 for leasing. This dual approach caters to different segments of the market, from startups with limited budgets to established businesses seeking premium domain names. The company’s revenue model is supported by secure transaction processes and customer service, fostering trust and encouraging repeat business from its growing client base.Diagnoplex plans to expand its product offerings with new domain name features aimed at enhancing user experience and transaction efficiency. In addition, the company is targeting growth in international markets, particularly in Europe and Asia, by the end of 2025. The recent funding of CHF 1.300 mn will be allocated to support product development and market expansion initiatives.

## Funding rounds

- Series A, Dec 10, 2008, $8.5M — Novartis Venture Fund, NeoMed, Initiative Capital Romandie
- Seed, Jun 1, 2005 — Novartis Venture Fund

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Seed, Series A
- NeoMed (https://capitalatlas.ai/funds/neomed) — Series A
- Initiative Capital Romandie — Series A